Memphis Pharmaceuticals results, Q1 2023
Net profit, assets, equity and cash flow for Q1 2023, against the same period a year earlier, from the published financial statements. fiscal year starts in July.
Net profit12.66 millionEGP · +386.7% vs the same period a year earlier
Total assets549 millionEGP · +25.6% vs the same period a year earlier
Shareholders' equity47.55 millionEGP · +209.0% vs the same period a year earlier
Operating cash flow-243 millionEGP · −11454.7% vs the same period a year earlier
In short
- Memphis Pharmaceuticals's net profit for Q1 2023 was about 12.66 million EGP, up +386.7% from -4.42 million EGP in Q1 2022.
- Total assets at the end of Q1 2023 were about 549 million EGP, and shareholders' equity about 47.55 million EGP.
- Operating cash flow for Q1 2023 was negative at 243 million EGP.
Key lines against the same period a year earlier
This periodQ1 2022Change
Net profit12.66 million-4.42 million+386.7%
Gross profit49.29 million27.34 million+80.3%
Total assets549 million437 million+25.6%
Total liabilities501 million481 million+4.3%
Shareholders' equity47.55 million-43.6 million+209.0%
Total liabilities and equity549 million437 million+25.6%
Operating cash flow-243 million2.14 million−11454.7%
Investing cash flow561 thousand1.24 million−54.7%
Financing cash flow294 million——
Net change in cash51.49 million3.38 million+1421.8%
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
Memphis Pharmaceuticals's Q1 2027 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy